These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26921250)

  • 1. Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.
    Huggett MT; Tudzarova S; Proctor I; Loddo M; Keane MG; Stoeber K; Williams GH; Pereira SP
    Oncotarget; 2016 Apr; 7(14):18495-507. PubMed ID: 26921250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cdc7-dependent and -independent phosphorylation of Claspin in the induction of the DNA replication checkpoint.
    Rainey MD; Harhen B; Wang GN; Murphy PV; Santocanale C
    Cell Cycle; 2013 May; 12(10):1560-8. PubMed ID: 23598722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xenopus Cdc7 executes its essential function early in S phase and is counteracted by checkpoint-regulated protein phosphatase 1.
    Poh WT; Chadha GS; Gillespie PJ; Kaldis P; Blow JJ
    Open Biol; 2014 Jan; 4(1):130138. PubMed ID: 24403013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
    Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
    EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
    Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
    Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
    Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
    Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.
    Rodriguez-Acebes S; Proctor I; Loddo M; Wollenschlaeger A; Rashid M; Falzon M; Prevost AT; Sainsbury R; Stoeber K; Williams GH
    Am J Pathol; 2010 Oct; 177(4):2034-45. PubMed ID: 20724597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
    Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
    EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress.
    Tudzarova S; Mulholland P; Dey A; Stoeber K; Okorokov AL; Williams GH
    Cell Cycle; 2016 Nov; 15(21):2958-2972. PubMed ID: 27611229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.
    Kulkarni AA; Kingsbury SR; Tudzarova S; Hong HK; Loddo M; Rashid M; Rodriguez-Acebes S; Prevost AT; Ledermann JA; Stoeber K; Williams GH
    Clin Cancer Res; 2009 Apr; 15(7):2417-25. PubMed ID: 19318489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.
    Sasi NK; Tiwari K; Soon FF; Bonte D; Wang T; Melcher K; Xu HE; Weinreich M
    PLoS One; 2014; 9(11):e113300. PubMed ID: 25412417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint.
    Kim JM; Kakusho N; Yamada M; Kanoh Y; Takemoto N; Masai H
    Oncogene; 2008 May; 27(24):3475-82. PubMed ID: 18084324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATR Restrains DNA Synthesis and Mitotic Catastrophe in Response to CDC7 Inhibition.
    Rainey MD; Bennett D; O'Dea R; Zanchetta ME; Voisin M; Seoighe C; Santocanale C
    Cell Rep; 2020 Sep; 32(9):108096. PubMed ID: 32877678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cdc7 as a potential new target for cancer therapy.
    Ito S; Taniyami C; Arai N; Masai H
    Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative proteomics reveals a "poised quiescence" cellular state after triggering the DNA replication origin activation checkpoint.
    Mulvey C; Tudzarova S; Crawford M; Williams GH; Stoeber K; Godovac-Zimmermann J
    J Proteome Res; 2010 Oct; 9(10):5445-60. PubMed ID: 20707412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors.
    Rainey MD; Quachthithu H; Gaboriau D; Santocanale C
    ACS Chem Biol; 2017 Jul; 12(7):1893-1902. PubMed ID: 28560864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells.
    Hou Y; Wang HQ; Ba Y
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2027-34. PubMed ID: 22806309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7.
    Im JS; Lee JK
    J Biol Chem; 2008 Sep; 283(37):25171-25177. PubMed ID: 18625709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular architecture of the DNA replication origin activation checkpoint.
    Tudzarova S; Trotter MW; Wollenschlaeger A; Mulvey C; Godovac-Zimmermann J; Williams GH; Stoeber K
    EMBO J; 2010 Oct; 29(19):3381-94. PubMed ID: 20729811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.